1774

Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype
Dallas R. English,1,4 Joanne P. Young,6,7 Julie A. Simpson,1,4 Mark A. Jenkins,1 Melissa C. Southey,2 Michael D. Walsh,6 Daniel D. Buchanan,6 Melissa A. Barker,6 Andrew M. Haydon,3 Simon G. Royce,5 Aedan Roberts,6 Susan Parry,8 John L. Hopper,1 Jeremy J. Jass,9 and Graham G. Giles1,4
1 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, and 2Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne; 3Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia; 4Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Victoria, Australia; 5Murdoch Childrens Research Institute, Parkville, Victoria, Australia; 6Familial Cancer Laboratory, Queensland Institute of Medical Research; 7 Faculty of Health Sciences, University of Queensland, Brisbane, Queensland, Australia; 8Department of Gastroenterology and Hepatology, Middlemore Hospital, Auckland, New Zealand; and 9Department of Cellular Pathology, St. Marks Hospital and Imperial College, Harrow, Middlesex, United Kingdom

Abstract
Colorectal cancers arising from serrated polyps are characterized by the CpG island methylator phenotype (CIMP) and somatic mutation (V600E) in the BRAF proto-oncogene. Few epidemiologic studies have investigated risk factors for these tumors. We conducted a cohort study of 41,328 residents of Melbourne, Australia that included 9,939 participants of southern European origin and 31,389 of Anglo-Celtic origin. Colorectal adenocarcinomas were identified from population-based cancer registries. BRAF V600E mutation in tumors was determined using a PCR-based allelic discrimination method. Tumors were classified as CIMP positive when at least three of five markers (RUNX3, CACNA1G, SOCS1, NEUROG1 , and IGF2 ) were methylated according to MethyLight analysis. Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated by Cox regression with adjustment for risk factors for colorectal cancer. During follow-up, 718 participants were diagnosed with colorectal cancer. CIMP assays were done for 579 and BRAF V600E mutation testing for 582. After adjustment for other risk factors, when compared with people of Anglo-Celtic origin, those of southern European origin had lower incidence of colorectal cancer that had CIMP (HR, 0.32; 95% CI, 0.16-0.67) or BRAF mutations (HR, 0.30; 95% CI, 0.16-0.58) but similar incidence of colorectal cancer without CIMP (HR, 0.86; 95% CI, 0.70-1.05) or BRAF (HR, 0.90; 95% CI, 0.74-1.11). People of southern European origin had lower risk of colorectal cancers with CIMP and BRAF mutation than people of Anglo-Celtic origin, which may in part be due to genetic factors that are less common in people of southern European origin. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1774 80)

Introduction
Colorectal cancer is a heterogeneous disorder for which molecular pathologic examination has identified distinct subsets that evolve through different pathways. One subset that arises from advanced serrated polyps rather than from adenomas has been identified (1-9). These tumors are characterized by activating somatic mutations in the BRAF proto-oncogene (10), predominantly V600E, and widespread hypermethylation of CpG islands, especially in the promoters of genes, referred to as the CpG island methylator phenotype (CIMP; refs. 11, 12). BRAF mutation and CIMP frequently co-occur in serrated polyps and their malignant counterparts (11-17). In addition, BRAF mutation has been identified in aberrant crypt foci, which show evidence of epithelial serration (18), suggesting that these changes are established early in colorectal carcinogenesis and induce commitment to the serrated neoplasia pathway (19). Different molecular subsets of colorectal cancer may have different environmental, genetic, and lifestyle risk factors, and investigation of possible risk factors separately for different molecular subtypes may lead to a better understanding of how to prevent disease. For example, in Australia, men have higher incidence of colorectal cancer than women (20), but CIMP and BRAF -related tumors are more common in women (21). Smoking was associated with risk of CIMP and BRAF -related tumors in a case-control study but not with other colorectal cancers (22), although there were no clear differences in dietary risk factors between the subtypes (23). The Melbourne Collaborative Cohort Study consists mostly of people of British or Irish descent (usually referred to in Australia as of Anglo-Celtic descent) and

Received 1/29/08; revised 4/3/08; accepted 4/22/08. Grant support: National Health and Medical Research Council grants 209057, 251533, 299955, and 442916; National Health and Medical Research Council Australia Fellowship 466668 (J.L. Hopper); and Cancer Council Queensland Senior Research Fellowship (J.P. Young). Cohort recruitment was partly funded by VicHealth. Requests for reprints: Dallas R. English, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Level 1, 723 Swanston Street, Parkville, Victoria 3010, Australia. Phone: 61-3-8344-0742; Fax: 61-3-9349-5815. E-mail: d.english@unimelb.edu.au Copyright D 2008 American Association for Cancer Research. doi:10.1158/1055-9965.EPI-08-0091

Cancer Epidemiol Biomarkers Prev 2008;17(7). July 2008

Cancer Epidemiology, Biomarkers & Prevention

1775

migrants to Australia from Greece or Italy (southern Europeans). The migrants were included to increase the heterogeneity of the cohort with respect to lifestyle (especially diet), genes, and rates of disease outcomes. When southern European migrants arrive in Australia, they initially have substantially lower mortality from colorectal cancer, but the differences diminish over time (24-26), suggesting that environmental factors after migration might be important risk factors. Within the Melbourne Collaborative Cohort Study, we determined CIMP and BRAF mutation status for colorectal cancers diagnosed during follow-up with a view to identifying those arising from the serrated pathway and determining whether their risk factors differed from the more common cancers that arise from adenomas. Here, we report on the incidence of colorectal cancer with CIMP and BRAF mutation in relation to ethnic origin and gender.

Materials and Methods

Subjects. The Melbourne Collaborative Cohort Study is a prospective cohort study of 41,528 participants, ages 27 to 75 years at recruitment from 1990 to 1994 (almost all were ages 40-69 years), and includes 5,425 migrants from Italy and 4,535 from Greece. For this analysis, 200 participants who had a colorectal cancer diagnosed before baseline were excluded, leaving 41,328. Subjects were recruited via the electoral rolls (registration to vote is compulsory for adults in Australia), advertisements, and community announcements in local media (e.g., television, radio, and newspapers). Comprehensive lists of Italian and Greek surnames were also used to target southern European migrants listed in the phone books and on electoral rolls. The study protocol was approved by the Cancer Council Victorias Human Research Ethics Committee. Participants gave written consent for participation and for the investigators to obtain their medical records. Baseline Data Collection. A structured interview schedule was used to obtain information on potential risk factors including education, country of birth, alcohol consumption, smoking habits, current physical activity during leisure time, education, and, for women, reproductive history, menopausal status including age at menopause, and use of hormone replacement therapy. Information on current diet was obtained from a dietary questionnaire that contained a 121-item food frequency questionnaire that was developed for this study (27). Height, weight, and waist and hip circumferences were measured. Cohort Follow-up and Case Ascertainment. Cases were participants who had a first diagnosis of invasive cancer of the colon or rectum during follow-up to December 31, 2004 and were identified by linkage to population-based cancer registries in all Australian states. Addresses and vital status of the subjects were determined by record linkage to electoral rolls, the National Death Index, Victorian death records, from electronic phone books, and from responses to mailed questionnaires and newsletters. Molecular Pathology. Archival tumor tissue was sought for all primary, histopathologically confirmed adenocarcinomas diagnosed in Victoria. Diagnosis was verified and pathology was reviewed by an experienced

histopathologist (J.R.J.). Immunohistochemistry for DNA mismatch repair genes MLH1, MSH2, MSH6 , and PMS2 was done as reported by Lindor et al. (28). Microsatellite instability (MSI) was examined using 10 microsatellite markers (28). BRAF V600E mutation analysis was done by a real-time PCR-based allelic discrimination method (29). CIMP status and MLH1 methylation was determined by MethyLight analysis of five markers (RUNX3, CACNA1G, SOCS1, NEUROG1 , and IGF2 ), and MLH1 , respectively (21). Exon 1 of KRAS was analyzed by direct sequencing (21). Positive methylation measurements were determined by the presence of amplification product for the five CIMP markers and MLH1 . Samples were considered negative for methylation if no marker-specific probe amplification was seen together with the Alu reference probe displaying amplification with a Ct value <25, indicating the initial amount of bisulfite converted template was significant enough to allow the amplification and detection of the methylation markers. Tumors were classified as CIMP positive when at least three markers were positive for methylation. For participants who had both colon and rectal tumors, results for colon tumors are reported here. Statistical Analysis. Ethnicity was defined based on country of birth and was classified into two groups: southern European (born in Italy or Greece) and Anglo-Celtic (born in Australia, New Zealand, United Kingdom, or Ireland). Cox regression, with age as the time scale, was used to estimate hazard ratios (HR), 95% confidence intervals (95% CI), and P values (30). To estimate HR separately for molecular subtypes and to test their difference, Cox models based on competing risks were fitted using a data duplication method (31). Calculation of person-time began at baseline and ended at the earliest of the date of diagnosis of colorectal cancer, date of diagnosis of cancer of unknown primary site, date of death, date last known to be in Australia, or December 31, 2004. Tests based on Schoenfeld residuals and graphical methods using Kaplan-Meier curves (32) showed no evidence that proportional hazard assumptions were violated for any analyses. Level of education, smoking status (never, former, current), alcohol intake (g/d), waist circumference, physical activity, frequency of red meat consumption, intakes of cereal fiber, calcium, dietary folate and energy, multivitamin use, calcium supplements, and, for women, hormone replacement therapy use were all considered as potential confounders. Only waist circumference and alcohol intake changed the HR for sex or ethnic origin by >10% and were retained in the final models. Differences between characteristics of tumors for which molecular measurements were done and those for which no measurements were made were tested using m2 tests for categorical variables and the MannWhitney rank sum test for continuous variables. All statistical tests are two sided, with P < 0.05 considered statistically significant. All statistical analyses were done in Stata version 9.2 (StataCorp).

Results
Baseline characteristics of the cohort by ethnic origin are shown in Table 1. Southern Europeans had larger mean

Cancer Epidemiol Biomarkers Prev 2008;17(7). July 2008

1776

Ethnicity and Risk for Colorectal Cancer

waist circumference than Anglo-Celts and were more likely to be lifetime abstainers from alcohol, to have lower educational attainment, less likely to engage in recreational physical activity, were more likely to eat red meat frequently, had lower intakes of cereal fiber, calcium, and folate, and were less likely to use multivitamins, calcium supplements, or hormone replacement therapy. Most of the migrants had lived in Australia for >30 years (median, 33 years; interquartile range, 28-37 years). During an average of 11 years of follow-up per person to December 31, 2004, 55 participants were known to have left Australia and 718 were diagnosed with colorectal cancer, including 449 with colon tumors (236 proximal and 173 distal), 269 with rectal tumors (three subjects had both colon and rectal tumors), and 40 with colorectal cancers of unspecified site. Archival tissue was obtained for 656 cases (92%); of the remaining cases, 9 were diagnosed in states other than Victoria, and for 53, the material could not be found or was not provided by the pathology laboratory. Molecular

analysis of archival tumor tissue was done for 585 cases for which CIMP status was determined for 579 and BRAF V600E mutation status for 582. Of those patients for whom no molecular analysis was attempted, 10 did not have a histopathologic diagnosis, and on review of the diagnostic slides, 25 were found to have metastatic disease, 11 were classified as having adenomas only, and 25 did not have tissue suitable for molecular analysis. A slightly lower proportion of tumors from men than from women had no molecular measurements (79% versus 84%; P = 0.05), but there was little difference in the proportions with molecular measurements by ethnicity (P = 0.8), age at diagnosis (P = 0.4), waist circumference (P = 0.1), smoking status (P = 0.3), alcohol consumption (P = 0.6), education (P = 0.4), physical activity (P = 0.3), red meat consumption (P = 0.8), or for the site (rectum, proximal, or distal colon; P = 0.7). CIMP and BRAF mutation status were strongly associated; 54 (74%) of 73 CIMP-positive tumors had BRAF mutations compared with 37 (7%) of 506 CIMP-negative tumors, giving an odds ratio of 36

Table 1. Baseline demographic, dietary, and lifestyle characteristics by ethnic origin

Ethnic origin Anglo-Celtic Total Age (y)* Waist circumference (cm)* Females c Smoking status (%) Never Former Current c Alcohol intake Lifetime abstainer Former drinker 1-19 g/d 20-39 g/d 40+ g/d c Education Primary school Some secondary school Completed secondary school Degree/diploma c Recreational physical activity None Low Medium High c Multivitamin use c Calcium supplement use c Hormone replacement therapy use (women only) Never Former Current c Red meat consumption (times a week) 0-4 5-6 7-9 10+ b Energy intake (kJ/d) b Cereal fiber intake (g/d) b Calcium intake (mg/d) b Folate intake (mg/d) 31,389 55.1 (8.9) 84 (13) 18,923 (60) 17,878 (57) 10,198 (32) 3,310 (11) 7,694 1,280 15,612 4,326 2,452 1,369 13,936 7,437 8,644 5,638 6,079 11,461 8,211 6,052 3,888 (25) (4) (50) (14) (8) (4) (44) (24) (28) (18) (19) (37) (26) (19) (12) Southern European 9,939 55.9 (7.8) 90 (12) 5,459 (55) 5,855 (59) 2,709 (27) 1,368 (14) 4,138 369 3,351 1,210 857 6,653 1,847 1,093 340 3,551 2,206 3,238 940 652 497 (42) (4) (34) (12) (9) (67) (19) (11) (3) (36) (22) (33) (9) (7) (5)

13,353 (71) 1,762 (9) 3,717 (20) 7,642 (24) 7,363 (24) 8,679 (28) 7,678 (24) 8,899 [7,090-11,101] 10.5 [7.5-14.5] 826 [633-1,064] 319 [249-405]

4,667 (87) 329 (6) 341 (6) 2,334 (24) 2,125 (21) 2,357 (24) 3,104 (31) 8,092 [6,287-10,414] 8.1 [5.5-11.5] 680 [509-908] 255 [187-344]

* Mean (SD). cNumbers do not always add up to total numbers due to missing data. bMedian [interquartile range].

Cancer Epidemiol Biomarkers Prev 2008;17(7). July 2008

Cancer Epidemiology, Biomarkers & Prevention

1777

Table 2. Characteristics of participants by colorectal cancer status during follow-up

Colorectal cancer diagnosed during follow-up No Negative Total Ethnic origin (%) Anglo-Celtic Southern European Sex (%) Female Male Alcohol intake (%) Lifetime abstainer Former drinker Low Medium High Waist circumference (cm)* Male Female Age at diagnosis (y)* Site (%) Proximal colon Distal colon Rectum Unknown MSI status High Intermediate Low Stable KRAS mutation MLH1 methylation
*Mean (SD).

CIMP Positive 73 89 11 67 33 30 7 36 18 10 95.2 (7.6) 83.5 (12.4) 68.3 (6.8) 84 8 7 1 49 0 7 44 15 62

BRAF V600E mutation status Negative 487 73 27 47 53 23 2 42 18 15 96.2 (9.4) 82.7 (12.3) 66.7 (8.0) 28 25 43 4 6 4 13 77 31 4 Positive 95 89 11 65 35 36 8 34 12 10 95.6 (9.5) 82.7 (11.8) 68.5 (6.6) 62 18 16 4 38 4 13 45 4 47

40,610 76 24 59 41 29 4 46 13 8 93.4 (10.3) 79.9 (12.0)

506 74 26 48 52 24 3 42 17 15 96.3 (9.5) 82.4 (12.1) 66.8 (7.9) 26 26 44 4 5 5 14 76 71 4

(95% CI, 19-71; P < 0.001). Both features were more common in tumors from females than from males (P < 0.005) and in tumors of the right colon (P < 0.005), were positively associated with MSI-high tumor status (P < 0.001) and MLH1 methylation (P < 0.001), and were inversely associated with KRAS mutations (P < 0.001; Table 2). Table 3 shows HR by sex and ethnic origin. Overall, women had a slightly lower incidence rate of colorectal cancer than did men (HR, 0.88; 95% CI, 0.74-1.05) and also had slightly lower incidence of tumors that were CIMP negative (HR, 0.84; 95% CI, 0.69-1.02) or that did not have BRAF mutations (HR, 0.83; 95% CI, 0.68-1.01) but had higher incidence rates for tumors that were CIMP positive or that had BRAF mutations (CIMP positive: HR, 1.83; 95% CI, 1.11-3.01; BRAF mutation: HR, 1.67; 95% CI, 1.08-2.58). For both molecular features, the differences between the HR for the two subtypes were significant. After adjustment for sex, alcohol intake, and waist circumference, people of southern European origin had f20% lower overall incidence of colorectal cancer than those of Anglo-Celtic origin (HR, 0.78; 95% CI, 0.65-0.93), 14% lower incidence rate of CIMP-negative tumors (HR, 0.86; 95% CI, 0.70-1.05) and 10% lower incidence of tumors without BRAF mutations (HR, 0.90; 95% CI, 0.741.11). In contrast, they had about one-third the rate of colorectal cancers that were CIMP positive (HR, 0.32; 95% CI, 0.16-0.67) or that had BRAF mutations (HR, 0.30; 95% CI, 0.16-0.58). For both molecular features, the

differences between the HR for the two subtypes were significant (Table 3). The HR for ethnicity in relation to tumors of the right colon were similar to those for all sites, although the 95% CI were wider (data not shown); P values for the differences between HR for the two subtypes were 0.07 for CIMP status and 0.008 for BRAF mutation status.

Discussion
Overall, people of southern European origin had f20% lower incidence rate of colorectal cancer than did people of Anglo-Celtic origin. This was largely due to their much lower incidence rate of tumors with BRAF mutations or the CIMP, because both ethnic groups had similar incidence rates of other colorectal cancer. Like others, we also found that BRAF mutation and CIMP were strongly associated with each other and were more common in tumors from females and the proximal colon (10, 21). In addition, also as reported previously, BRAF mutation was positively associated with MSI-high status and MLH1 methylation and inversely associated with the presence of KRAS in a tumor (33). Our study has several strengths and limitations. We had almost complete ascertainment of colorectal cancer and little loss to follow-up but were unable to obtain archival tissue from the primary lesion for 19% of cases. However, this is unlikely to have biased the observed associations because the proportions of cases with no

Cancer Epidemiol Biomarkers Prev 2008;17(7). July 2008

1778

Ethnicity and Risk for Colorectal Cancer

suitable tissue varied little by ethnicity or sex. Our measurement of CIMP used a panel of recently reported markers with high sensitivity and specificity, and the associations between CIMP and BRAF mutation status, MSI status, MLH1 methylation, KRAS mutations, and subsite are supported by earlier studies, indicating that our measurements of CIMP and BRAF mutation status are in general agreement with those of other investigators (21). Despite residing in Australia for many years, the migrants maintained substantial differences in dietary patterns from those born in Australia (34) and also differed from the Australian-born participants in their smoking habits, alcohol intake, waist circumference, and education. Nevertheless, control for these risk factors had little effect on the results. It is unlikely that family history, which was not recorded, could account for a strong inverse association between southern European descent and risk of tumors with CIMP or BRAF mutation status but little or no association with risk of tumors not displaying these features. We cannot rule out chance as an explanation for the ethnic differences in risk of BRAF -related colorectal cancer. The HR for all colorectal cancer for the southern European migrants (0.78) is consistent with descriptive studies of mortality. Compared with Australian-born residents, migrants who had lived in Australia for at least 30 years had mortality rate ratios between 0.7 (25) and 0.8 (95% CI, 0.7-1.0; ref. 26). This suggests that although migrants risk for the more common form of colorectal cancer converges to that of the Australian born with increasing duration of residence, the same is not true for tumors with BRAF mutation or the CIMP. Risk factors that act primarily before migration, or genetic factors (35, 36), could explain the lack of convergence for these tumor types.

Evidence for a genetic predisposition for tumors bearing BRAF mutations comes from a case-control study of colorectal cancer, where microsatellite-stable tumors with BRAF mutation were over four times more likely than tumors without BRAF mutation to be associated with a family history of colorectal cancer (37). In addition, familial syndromes associated with BRAF mutation-bearing tumors have been described from Australia and Sweden (29, 38). There is also indirect evidence regarding an association between ethnicity and the risk of colorectal cancer with CIMP and BRAF mutation from a study of hyperplastic polyposis syndrome, which is a rare condition characterized by multiple serrated polyps and tumors with CIMP and BRAF mutation. In a case series from a gastroenterology clinic in New Zealand, all 24 cases were people of European origin, whereas only 46% of patients attending the clinic were of European descent (39). Thus, the possibility exists that a sequence variant in the AngloCeltic population may underlie the development of CIMP-related colorectal cancer either directly or through modulation of an environmental influence; however, at present, none has been definitively identified. Two studies have examined associations between common genetic variants and CIMP status for patients with colorectal cancer, including genes in the folate pathway. van Rijnsoever et al. found that overall there was no association between a variant in the 5,10-methylenetetrahydrofolate reductase gene (C677T; rs1801133) and type of colorectal cancer, but that females had a higher proportion of CIMP-positive tumors (40). CIMP was defined as methylation of two of three genes (CDKN2A, MDR1 , and MINT2 ). Paz et al. observed that the mean proportion of methylation in six genes (CDKN2A, p14ARF, MGMT, APC, LKB1 , and MLH1 )

Table 3. HR for sex and ethnic origin according to type of colorectal cancer
Type of colorectal cancer Male Person-years All colorectal cancer Cases c Partially adjusted b Fully adjusted CIMP status Positive Cases c Partially adjusted b Fully adjusted Negative Cases c Partially adjusted b Fully adjusted BRAF mutation status Positive Cases c Partially adjusted b Fully adjusted Negative Cases c Partially adjusted b Fully adjusted 187,654 371 1 1 24 1 1 266 1 1 33 1 1 257 1 1 Sex Female 277,942 347 0.65 (0.57-0.80) 0.88 (0.74-1.05) 49 1.37 (0.84-2.24) 1.83 (1.11-3.01) 240 0.63 (0.53-0.75) 0.84 (0.69-1.02) 62 1.26 (0.83-1.93) 1.67 (1.08-2.58) 230 0.63 (0.52-0.75) 0.83 (0.68-1.01) P* Anglo-Celtic 346,149 545 1 1 65 1 1 374 1 1 85 1 1 356 1 1 Ethnic origin Southern European 119,447 173 0.84 (0.70-0.99) 0.78 (0.65-0.93) 8 0.35 (0.17-0.72) 0.32 (0.16-0.67) 132 0.92 (0.76-1.12) 0.86 (0.70-1.05) 10 0.33 (0.17-0.62) 0.30 (0.16-0.58) 131 0.96 (0.79-1.18) 0.90 (0.74- 1.11) P*

0.003

0.011

0.003

0.002

* P value for test that fully adjusted HR for two tumor subtypes are equal. cHR (95% CI) adjusted for both variables in the table and with age as the time scale. bHR (95% CI) adjusted for both variables in the table plus waist circumference and alcohol intake and with age as the time scale.

Cancer Epidemiol Biomarkers Prev 2008;17(7). July 2008

Cancer Epidemiology, Biomarkers & Prevention

1779

was higher for colorectal cancer patients with a polymorphism in the gene coding 5-methyltetrahydrofolate-homocysteine methyltransferase, also known as methionine synthase reductase (41). Other genes involved in the folate pathway, those encoding including 5-methyltetrahydrofolate-homocysteine methyltransferase and thymidylate synthetase, have been shown to be associated with colorectal cancer in general (42). Colorectal cancers with CIMP and BRAF mutation arise in a subset of serrated polyps called sessile serrated adenomas (3). Given our findings, it is likely that sessile serrated adenomas, lesions with high levels of BRAF mutation (10), may also be more common in people of Anglo-Celtic descent than in people of southern European descent. The prevalence of these lesions in patients undergoing colonoscopy ranges from 4% to 9% (43, 44) and is associated with increased polyp burden (44). CIMP tumors are frequently located in the proximal colon (40), and the detection of their sessile precursor lesions may prove difficult (45). CIMP-related colorectal tumors have been shown to account for almost all nonfamilial MSI-high colorectal cancers (11) and are associated with improved survival for this subgroup (46). In contrast, tumors that show somatic BRAF mutation in the absence of a MSI-high phenotype may have a relatively poor outcome (37). In summary, we have confirmed the findings of Weisenberger et al. (21) that their five-marker panel effectively identifies CIMP colorectal cancer and its association with BRAF mutation, female sex, proximal location in the colon, MSI-high tumor status, and MLH1 methylation. Further, we report the novel finding that individuals with Anglo-Celtic ancestry were more likely to develop CIMP-related colorectal cancer than were individuals of Italian or Greek origin, and this difference was unlikely to be due to environmental factors commonly associated with colorectal cancer.

2.

3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15.

16.

17.

18.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
19. 20.

Acknowledgments
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. We thank Peter Laird for extensive advice in the performance of MethyLight assays, Veronika Gavdik for laboratory assistance, Lesley Jaskowski for the preparation of data for this article, and the pathology laboratories that provided archived tissue for the project. This study was made possible by the contribution of many people, including the original investigators, the Program Manager, Georgina Marr, and the diligent team who recruited the participants and who continue working on follow-up. The authors express their gratitude to the many thousands of Melbourne residents who continue to participate in the study.

21.

22. 23. 24. 25. 26.

References
1. Biemer-Huttmann AE, Walsh MD, McGuckin MA, et al. Immunohistochemical staining patterns of MUC1, MUC2, MUC4, and MUC5AC mucins in hyperplastic polyps, serrated adenomas, and traditional adenomas of the colorectum. J Histochem Cytochem 1999; 47:1039 48. 27.

28.

Biemer-Huttmann AE, Walsh MD, McGuckin MA, et al. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res 2000;6:1909 16. Goldstein NS. Clinical significance of (sessile) serrated adenomas: another piece of the puzzle. Am J Clin Pathol 2005;123:329 30. Goldstein NS, Bhanot P, Odish E, Hunter S. Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am J Clin Pathol 2003;119:778 96. Jass JR. Serrated route to colorectal cancer: back street or super highway? J Pathol 2001;193:283 5. Jass JR. Hyperplastic polyps of the colorectuminnocent or guilty? Dis Colon Rectum 2001;44:163 6. Jass JR. Hyperplastic-like polyps as precursors of microsatelliteunstable colorectal cancer. Am J Clin Pathol 2003;119:773 5. Jass JR, Iino H, Ruszkiewicz A, et al. Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut 2000;47:43 9. Jass JR, Young J, Leggett BA. Hyperplastic polyps and DNA microsatellite unstable cancers of the colorectum. Histopathology 2000;37:295 301. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004;53:1137 44. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681 6. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999;59:2307 12. Beach R, Chan AO, Wu TT, et al. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 2005;166:1069 75. Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol 2002; 160:529 36. OBrien MJ, Yang S, Clebanoff JL, et al. Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol 2004;28:423 34. OBrien MJ, Yang S, Mack C, et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 2006;30:1491 501. Yang S, Farraye FA, Mack C, Posnik O, OBrien MJ. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 2004;28:1452 9. Rosenberg DW, Yang S, Pleau DC, et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 2007;67:3551 4. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113 30. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2006. Cancer series no. 37. Cat. no. CAN 32. Canberra: Australian Institute of Health and Welfare; 2007. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787 93. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006;98:1731 8. Slattery ML, Curtin K, Sweeney C, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007;120:656 63. McMichael AJ, McCall MG, Hartshorne JM, Woodings TL. Patterns of gastro-intestinal cancer in European migrants to Australia: the role of dietary change. Int J Cancer 1980;25:431 7. Balzi D, Khlat M, Matos E. Cancer in Italian migrant populations. Australia: mortality study. IARC Sci Publ 1993;123:125 37. McCredie M, Williams S, Coates M. Cancer mortality in migrants from the British Isles and continental Europe to New South Wales, Australia, 1975-1995. Int J Cancer 1999;83:179 85. Ireland P, Jolley D, Giles GG, et al. Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pac J Clin Nutr 1994;3:19 31. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry

Cancer Epidemiol Biomarkers Prev 2008;17(7). July 2008

1780

Ethnicity and Risk for Colorectal Cancer

29.

30. 31. 32. 33. 34. 35. 36. 37. 38.

versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043 8. Young J, Barker MA, Simms LA, et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 2005;3:254 63. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72 80. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995;51:524 32. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Statistics for biology and health. New York: Springer; 2000. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451 5. Harriss LR, English DR, Powles J, et al. Dietary patterns and cardiovascular mortality in the Melbourne Collaborative Cohort Study. Am J Clin Nutr 2007;86:221 9. Young J, Jass JR. The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. Cancer Epidemiol Biomarkers Prev 2006;15:1778 84. Young J, Jenkins M, Parry S, et al. Serrated pathway colorectal cancer in the population: genetic consideration. Gut 2007;56:1453 9. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063 9. Vandrovcova J, Lagerstedt-Robinsson K, Pahlman L, Lindblom A.

39.

40. 41.

42.

43. 44. 45. 46.

Somatic BRAF-V600E mutations in familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2270 3. Yeoman A, Young J, Arnold J, Jass J, Parry S. Hyperplastic polyposis in the New Zealand population: a condition associated with increased colorectal cancer risk and European ancestry. N Z Med J 2007;120:31 39. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002;51:797 802. Paz MF, Avila S, Fraga MF, et al. Germ-line variants in methylgroup metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002;62: 4519 24. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML. Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2005;14:2509 16. Higuchi T, Sugihara K, Jass JR. Demographic and pathological characteristics of serrated polyps of colorectum. Histopathology 2005;47:32 40. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006;131:1400 7. Farrar WD, Sawhney MS, Nelson DB, Lederle FA, Bond JH. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol 2006;4:1259 64. Wright CM, Dent OF, Barker M, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000;87:1197 202.

Cancer Epidemiol Biomarkers Prev 2008;17(7). July 2008